Granahan Investment Management’s LeMaitre Vascular LMAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-245,086
Closed -$4.86M 236
2016
Q3
$4.86M Sell
245,086
-253,870
-51% -$4.44M 0.16% 151
2016
Q2
$7.12M Buy
498,956
+22,660
+5% +$346K 0.26% 130
2016
Q1
$7.39M Buy
476,296
+6,260
+1% +$89.8K 0.27% 129
2015
Q4
$8.11M Sell
470,036
-213,245
-31% -$3.09M 0.28% 119
2015
Q3
$8.33M Sell
683,281
-132,801
-16% -$1.7M 0.26% 131
2015
Q2
$9.84M Buy
816,082
+92,090
+13% +$907K 0.28% 130
2015
Q1
$6.07M Buy
723,992
+9,850
+1% +$77.3K 0.17% 165
2014
Q4
$5.46M Sell
714,142
-9,790
-1% -$70.1K 0.16% 158
2014
Q3
$4.98M Sell
723,932
-18,541
-2% -$138K 0.15% 163
2014
Q2
$6.14M Sell
742,473
-45,582
-6% -$356K 0.18% 157
2014
Q1
$6.36M Buy
788,055
+1,640
+0.2% +$13.1K 0.17% 164
2013
Q4
$6.3M Buy
786,415
+818
+0.1% +$6.33K 0.16% 160
2013
Q3
$5.26M Buy
785,597
+30,620
+4% +$207K 0.14% 169
2013
Q2
$4.94M Buy
+754,977
New +$4.76M 0.14% 167

Other funds holding LMAT

Granahan Investment Management's LMAT Position: Q4 2016 in Review

Granahan Investment Management sold out of LeMaitre Vascular (LMAT) in Q4 2016, closing a stake of 245,086 shares — an estimated $4.86M sold.

Granahan Investment Management first reported a position in LMAT in Q2 2013 and held it in 14 quarters. The position peaked at $9.84M in Q2 2015. 112 funds tracked by Wall St. Rank hold LMAT as of Q4 2016.

  • Granahan Investment Management reported no remaining LeMaitre Vascular position as of Q4 2016 after selling out during the quarter.
  • Granahan Investment Management sold 245,086 LeMaitre Vascular shares in Q4 2016, an estimated $4.86M.
  • Granahan Investment Management first reported a position in LeMaitre Vascular in Q2 2013 and held it in 14 quarters.
  • Granahan Investment Management's LeMaitre Vascular position peaked at $9.84M in Q2 2015.
  • 112 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2016.

Based on Granahan Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.